BRAF and neoplasm: Among the most clinically relevant studies, Tsai and collaborators proved the anti-tumor potential of the mutated-BRAF selective inhibitor (PLX4720) in BRAFV600E-dependent tumor xenograft models, inducing a significant tumor growth delay and even regression [24].